Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-26 @ 4:07 AM
Study NCT ID:
NCT01833494
Status:
COMPLETED
Last Update Posted:
2018-10-09
First Post:
2013-04-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Sponsor:
Kissei Pharmaceutical Co., Ltd.
Organization:
Study Overview
Official Title:
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: